These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 29315503)

  • 21. Nivolumab and its use in the second-line treatment of metastatic urothelial cancer.
    Raggi D; Necchi A; Giannatempo P
    Future Oncol; 2018 Nov; 14(26):2683-2690. PubMed ID: 29927336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
    BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab for the treatment of colorectal cancer.
    Coupez D; Hulo P; Touchefeu Y; Bossard C; Bennouna J
    Expert Opin Biol Ther; 2020 Mar; 20(3):219-226. PubMed ID: 31952453
    [No Abstract]   [Full Text] [Related]  

  • 24. Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors.
    Tolba MF
    Int J Cancer; 2020 Dec; 147(11):2996-3006. PubMed ID: 32415713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Making precision oncology the standard of care.
    The Lancet Oncology
    Lancet Oncol; 2017 Jul; 18(7):835. PubMed ID: 28677559
    [No Abstract]   [Full Text] [Related]  

  • 26. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.
    Boyiadzis MM; Kirkwood JM; Marshall JL; Pritchard CC; Azad NS; Gulley JL
    J Immunother Cancer; 2018 May; 6(1):35. PubMed ID: 29754585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in colorectal cancer with mismatch repair deficiency.
    Overman MJ
    Clin Adv Hematol Oncol; 2019 May; 17(5):265-267. PubMed ID: 31188802
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapy in colorectal cancer.
    Agarwal P; Le DT; Boland PM
    Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.
    Ciardiello D; Vitiello PP; Cardone C; Martini G; Troiani T; Martinelli E; Ciardiello F
    Cancer Treat Rev; 2019 Jun; 76():22-32. PubMed ID: 31079031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytolytic Activity Score to Assess Anticancer Immunity in Colorectal Cancer.
    Narayanan S; Kawaguchi T; Yan L; Peng X; Qi Q; Takabe K
    Ann Surg Oncol; 2018 Aug; 25(8):2323-2331. PubMed ID: 29770915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.
    Shen Y; Guan Y; Hummel JJ; Shyu CR; Mitchem JB
    BMC Cancer; 2020 Feb; 20(1):124. PubMed ID: 32059711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immune response and colorectal cancer].
    Tougeron D; Fauquembergue E; Latouche JB
    Bull Cancer; 2013 Mar; 100(3):283-94. PubMed ID: 23501583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immune response and digestive cancers: Prognostic and therapeutic implications].
    Bibeau F; Bazille C; Svrcek M; Pierson R; Lagorce-Pagès C; Cohen R; André T
    Ann Pathol; 2017 Feb; 37(1):111-116. PubMed ID: 28111038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug resistance and new therapies in colorectal cancer.
    Van der Jeught K; Xu HC; Li YJ; Lu XB; Ji G
    World J Gastroenterol; 2018 Sep; 24(34):3834-3848. PubMed ID: 30228778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer.
    Chen Y; Zheng X; Wu C
    Front Immunol; 2021; 12():792691. PubMed ID: 34925375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomics and emerging biomarkers for immunotherapy of colorectal cancer.
    Kather JN; Halama N; Jaeger D
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):189-197. PubMed ID: 29501787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting.
    Puccini A; Lenz HJ
    Nat Rev Clin Oncol; 2018 Feb; 15(2):77-78. PubMed ID: 29182161
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Precision medicine for metastatic colorectal cancer: an evolving era.
    Guler I; Askan G; Klostergaard J; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2019 Oct; 13(10):919-931. PubMed ID: 31475851
    [No Abstract]   [Full Text] [Related]  

  • 40. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management.
    Overman MJ; Ernstoff MS; Morse MA
    Am Soc Clin Oncol Educ Book; 2018 May; 38():239-247. PubMed ID: 30231358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.